Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Archive
- 2024/Volume 20
- 2023/Volume 19
- 2022/Volume 18
- 2021/Volume 17
- 2020/Volume 16
- 2019/Volume 15
- 2018/Volume 14
- 2017/Volume 13
- 2016/Volume 12
- 2015/Volume 11
Therapy and prognosis of metastatic prostate cancer
Deadline for manuscript submissions: 31 August 2021
Print Special Issue Flyer (37)Special Issue Editor
Guest Editor
PhD, Department of Oncology, Petz Aladár Hospital, Győr, Hungary
Interests: Infections and malignancies of the urinary tract, Diagnosis of “fever of unknown origin”, Oncologic emergencies, Pain relief for cancer patients
Special Issue Information
Dear Colleagues,
Please let me invite you to contribute to the preparation and later to favour a mindful lecture of this speciel issue of the Journal of Men’s Health dedicated to metastatic prostate cancer.
Although being a leading cause of cancer death, metastatic prostate cancer, compared to other cancer types, is any longer necesserily a life threatening condition. Thanks to recent pharmaceutical developments, several lines of anti-hormonal and cytostatic treatments may provide long years of disease control.
We would like to focus in this special issue to the diagnostic challenges, to the proper use of innovative therapies and to the patients’ perspectives open with the improved prognosis. Differentiating between localised and generalised disease remains problematic even with the best imaging techniques. Sequencing and maintenance of novel drugs are being debated. The men’s own evaluation of the quality of their prolonged life is maybe not enough taken into account.
This special issue offers an opportunity to address the following but other topics:
- Diagnosis and treatment of oligometastatic disease
- Diagnosis and treatment of micrometastatic disease
- Diagnosis and treatment of neuroendocrin cancer of the prostate
- Optimal selection of systemic therapies
- Optimal maintenance of second line antiandrogenic therapies
- Optimal comedication of androgen synthesis inhibitors
- Optimal dosing of bisphosphonates
- Quality of life of patients with metastatic prostate cancer
Let’s share our experience to the better care of the patients of all of us.
Yours,
Kullmann Tamás
Keywords
Prostate cancer, Metastatic prostate cancer, Diagnosis, Treatment, Prognosis, Quality of life, Oligometastatic disease, Micrometastatic disease, Androgen synthesis inhibitors, Second line antiandrogenic therapies, Bisphosphonates
Manuscript Submission Information
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. JOMH is an international peer-reviewed open access journal published by MRE Press. As of January 2021, JOMH will change to a monthly journal. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $2000. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Share This Special Issue
Published Papers (12 papers)
A comprehensive mechanistic basis of prostate cancer advancement & its personalized implementation-bridging the gap: present state and future prospect
A comprehensive mechanistic basis of prostate cancer advancement & its personalized implementation-bridging the gap: present state and future prospect
DOI: 10.31083/jomh.2021.029
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
DOI: 10.31083/jomh.2021.041
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysis
The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysis
DOI: 10.31083/jomh.2021.053
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Insights into association between urolithiasis and prostate cancer
Insights into association between urolithiasis and prostate cancer
DOI: 10.31083/jomh.2021.070
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
The diagnostic value of a new formula combining age and prostate volume in prostate cancer
The diagnostic value of a new formula combining age and prostate volume in prostate cancer
DOI: 10.31083/jomh.2021.080
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening program
Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening program
DOI: 10.31083/jomh.2021.081
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Decrease in prostate cancer detection during COVID-19 pandemic
Decrease in prostate cancer detection during COVID-19 pandemic
DOI: 10.31083/jomh.2021.110
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer
A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer
DOI: 10.31083/jomh.2021.133
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Neuroendocrine cancer of the prostate. Two case reports
Neuroendocrine cancer of the prostate. Two case reports
DOI: 10.31083/j.jomh1803065
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer
Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer
DOI: 10.31083/j.jomh1807155
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Prostatic signet-ring adenocarcinoma: A case report
Prostatic signet-ring adenocarcinoma: A case report
DOI: 10.31083/j.jomh1804090
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer
Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer
DOI: 10.31083/j.jomh1804093
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Abstracted / indexed in
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)
Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.
Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).